Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in MDD Patients on SSRIs
NCT05594667Phase 2Withdrawn
- Sponsor
- Cybin Inc.
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Cybin Inc. Primary endpoint: Quick Inventory of Depressive Symptomatology-Self-Report at 12 weeks. Planned start Jan 2023; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05594667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594667.